Biogen's Alzheimer's drug loses subsidies in the US

The US government is limiting its coverage of Biogen's Alzheimer's drug, Aduhelm, due to the risk of adverse effects. Biogen's stock plummets.

Photo: Pool New/Reuters/Ritzau Scanpix

The US government will cut the subsidies available for Biogen's controversial Alzheimer's drug, Aduhelm, and the decision is being felt on the US stock post-market on Tuesday, reports Bloomberg News.

Coverage of Aduhelm is now limited to clinical trial participants, meaning that subsidies going to regular patients on Medicare in the US will disappear.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs